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Purpose: Brown adipose tissue (BAT) research has evolved from an underestimated to a fast developing
field. Its assumed curing properties for the world wide epidemic obesity, and its related diseases, makes
this tissue an interesting target for a broad amount of non-invasive molecular BAT tracers. Apart from
18F-FDG PET/CT there are several methods to detect BAT and measure its metabolism in a more appropri-
ate way. Especially interesting is the measure of lipid turnover, because fatty acids comprise the main
fuel for active BAT. This review outlines different imaging modalities suitable for BAT imaging with
the overall goal to explain the yet not completely understood mechanism in BAT and its quantitative con-
tribution to whole body lipid and energy metabolism.
Methods: Publications with focus on brown adipose tissue and lipid metabolism imaging are analyzed,
different imaging approaches are introduced and promising BAT tracers are presented.
Results: Radiolabelled and fluorescent fatty acids, labelled particles, 3H-Triolein and ADIFAB staining can
give information about the inflow and therefore about the utilization of fatty acids which represents the
activation state in vivo/in vitro. Non-invasive scanning with CT or MRI is a useful addition to those tech-
niques.
Conclusion: Lipid metabolism imaging offers the opportunity to visualize and quantify yet undiscovered
aspects of BAT metabolic activities and is key to completely clarify its role in whole body lipid and energy
metabolism.
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1.1. Background
The function and presence of BAT in adults was neglected until
two decades ago. Now the investigation of BAT using molecular
imaging has matured to one of the most interesting and fast devel-
oping research topics in endocrine research. Because obesity – and
its related metabolic syndrome – is reaching epidemic proportions
in the western world [1] andmay even become amore severe prob-
lem in the near future for theworldwide population,more attention
is drawn to adipose tissue metabolism. A turning point was the dis-
covery that WAT, apart from storing energy (fat), is able to secret
leptin, an important hormone controlling the energy balance [2].
Other substances [3] (autocrine and endocrine) released by WAT
have been found and by that the consideration of the impact of adi-
pose tissue on whole body metabolism rose continuously. In retro-
spective PET studies with FDG, it could be shown that besidesWAT,
another form of adipose tissue exists in adult humans [4–6]. In
these studies, symmetrical accumulations of FDG appeared in the
supraclavicular region, which were originally thought to be attrib-
uted to uptake in cervical muscles. Later, scans with PET/CT indi-
cated that these ‘‘artifacts” correlate with Hounsfield units of fat
[6]. By these FDG studies it could be proven that BAT is functionally
present in adults and is metabolically active. BAT, named after its
darker color resulting from higher mitochondria expression within
the cell and increased blood circulation [7], was previously thought
to be absent in adult humans and only be present in newborns to
maintain their body temperature [8]. The results of the PET scans
indicate a chance of observing BAT in 5–8% of standard clinical rou-
tine PET scans [4,9] and a total contribution to body mass of 0,05–
0,01% [10]. These findings could be confirmed later by dedicated
cold exposure studies where a direct correlation between cold
exposure and BAT metabolic activity, measured through FDG
uptake, was reported [11–13]. Assuming a fixed relative contribu-
tion of glucose and fatty acids and that mainly fatty acids and glu-
cose contribute to energy expenditure [12,14], an increase in
metabolic activity of BAT would result in an increase of total body
energy expenditure of 2–28% [15]. Therefore activation of BAT with
unchanged food uptake, may lead to significant weight loss, offer-
ing an additional treatment option to obese patients. Another field
of applicationwould be in patients with pheochromocytoma. It was
found that catecholamine secreting tumors activate BAT and lead to
an increase in metabolic activity characterized by FA and glucose
uptake [16–18]. In these studies BAT activity was inversely corre-
lated to body mass index and in general patients with cancer
cachexia are often suffering from body weight loss and depletion
of muscular and adipose tissue [19].However, in order to actually calculate the metabolic activity of
BAT in humans, in addition to FDG PET/CT, other tracers and tech-
niques are needed. Through the upcoming interest in this tissue,
several new activation, targeting and imaging strategies have been
developed to visualize BAT’s functions. FDG has set the stage; sev-
eral attributions of BAT have been defined. Non-invasive visualiza-
tion of lipid metabolism could give more insight since lipid
turnover is one of the major features of BAT. This review summa-
rizes early as well as the newest inventions of lipid metabolism
imaging linked to BAT and describes how visualization of lipid fate
and adipose tissue activity has evolved.
1.2. Activation of brown adipose tissue and fatty acid metabolism
First observations of BAT in humans were performed with FDG
[4–6] which visualizes metabolic active tissue in terms of glucose
uptake. It was observed that through cold exposure the chance of
visualizing BAT increased in animals and lean subjects [11–13].
Besides, it was shown that BAT is activated through nore-
pinephrine binding to b3-adrenoeceptor [20,21]. Recently it was
observed for the first time that BAT takes up an increased amount
of glucose in obese humans after cold acclimation. This led to the
conclusion that significant amounts of BAT can be recruited during
repeated cold exposure [22]. Glucose is mainly taken up by protein
transporters of the GLUT family, mainly the fat muscle specific iso-
form GLUT4 [23,24]. Glucose is processed in different pathways e.g.
in citric acid cycle [25] or it is conversed to FA [26,27]. Neverthe-
less LCFA are the main ‘‘fuel” for BAT. Tracers based on fatty acids,
quantify the metabolic activity of BAT in a better way than glucose
does.
Through the norepinephrine activation process FA stored as TG
in lipid droplets are consumed in the mitochondria to produce heat
and new FA are taken up [28,29]. This identifies FA as the main
metabolized substance in BAT and makes them and other com-
pounds targeting lipid metabolism a powerful tool to visualize
BAT and its functions within the body.
Usually mitochondria oxidize fatty acids and ATP is produced to
store the nascent energy but BAT mitochondria contain the BAT
specific UCP1 which gives them the ability to uncouple the oxida-
tion process and to produce heat instead of ATP [30–33]. This pro-
cess is responsible for nonshivering thermogenesis [15,34].
Fedorenko et al. showed that LCFA (>12 carbon atoms [35]) are
essential for the uncoupling process as they work as a carrier for
H+ through the UCP1 and that LCFA are also produced within the
inner mitochondria membrane by PLA2 [36]. In BAT cells UCP1 is
inhibited by purine nucleotides, mainly ATP. The UCP1 channel is
blocked by the nucleotides from the cytosolic side [37–40]. It
was shown that LCFA can overcome the blocking of UCP1 and
Fig. 1. TRLs are hydrolyzed by LPL and FA can bind to albumin. After dissociation from albumin, FA bind to membrane proteins such as CD36 or directly to FATP. A direct
diffusion through the membrane is possible but dependent on free FA concentrations and FA already taken up by the cells [118]. FA from CD36 are handed to FATP and are
transported through the membrane where they are either processed as FA or activated and coupled to coenzyme A (CoA) by ACSL. Free FA can then be stored in lipid droplets
as TG after esterification or directly processed in the mitochondria.
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vation through LCFA also confirms the observation that lipolysis
activates thermogenesis in the same order of magnitude than nore-
pinephrine does [42,43].
As quoted before, stored TGs in BAT can be utilized for combus-
tion or FA can be taken up after lipolysis by BAT. Uptake of FA from
external sources by a brown adipocyte is realized by protein medi-
ated transport [44], nevertheless the exact mechanism of FA
uptake is unclear. FA are transported in TRLs by the blood. BAT
uptake of FA via internalization of these particles, via direct FA
uptake after lipolysis related breakup of TRLs or a combination of
both is possible. Khedoe et al. equipped TRLs of different size with
3H-oleate and 14C-cholesteryl oleate [45]. At room temperature a
lipolysis supported uptake could be observed as cholesteryl oleate
stays within the particle core due to its hydrophobicity and most
taken up activity in BAT resulted from 3H-oleate. Left over remnant
particles, containing a higher ratio of 14C-cholesteryl oleate are
cleared by the liver which explains why a much higher
14C-activity compared to 3H-activity can be observed in the liver.
Also cold exposure or thermoneutrality did not promote internal-
ization of TRLs in BAT cells in an important amount but of course
changed the amount of FA taken up by BAT [45].
In contrast to these experiments is the finding of Bartelt et al.
They labelled TRLs with 3H-oleate and hydrophobic 59Fe-SPIOnanocrystals [46]. As a result of lipolysis 3H-oleate can enter the
cell whereas 59Fe-SPIO nanocrystals stay inside of the TRL’s. In cold
exposed mice a significant faster clearance of 3H-oleate and 59Fe-
SPIO and a tenfold higher uptake of both imaging agents in BAT
is reported. Through intravital microscopy a rapid attachment to
the endothelium, followed by an internalization of the TRLs could
be observed [46]. Bartelt et al. explain their observations that
through lipolysis products the endothelial barrier function is
decreased and TRLs can enter the cell [47].
The discrepancy between both experiments may be explained
by different imaging agents used and therefore different uptake
mechanisms are needed to explain the results. Nevertheless, the
dominant uptake mechanism (lipolysis assisted uptake of FA or
internalization of TGLs) is not determined at the moment and
needs to be established by other imaging approaches and
experiments.
In terms of lipolysis, LPL is the first of multiple proteins
involved in the process of FA uptake into BAT [29,48,49]. Other
important proteins related to FA uptake of BAT are fatty acid
translocase (FAT/CD36) [50], fatty acid transport proteins (FATPs)
[51] and fatty acyl-CoA synthetases (ACSL) [52]. The common
way of FA uptake is described as in Fig. 1, according to [48].
Different studies have identified LPL and CD36 as indispensable
factors for FA uptake and a loss of one of these proteins results in
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increased glucose uptake and hypothermia during fasting and cold
exposure [53,54].
LCFA can also be produced through lipogenesis within the cell
by fatty acid synthase up to a carbon chain length of 16 carbon
atoms [29]. Elongation to very long chain fatty acids is done by
very long chain fatty acids enzymes (ELOVL) where ELOVL3 was
found to be overexpressed in cold exposed BAT and mice lacking
of ELOVL3 where only able to survive cold by shivering thermoge-
nesis [55]. These findings indicate lipogenesis as an essential fea-
ture to ensure the TG amount necessary during cold exposure.
Its high amount of mitochondria and multilocular lipid droplets
make BAT appear more like muscle than adipose tissue [15].
1.3. White adipose tissue, fat storage and endocrine function
The main function of WAT is fat storage and fatty acid secretion.
When energy intake is higher than consumption, fatty acids are
stored in WAT. In times of fasting or cold exposure, WAT is acti-
vated to release its fuel (fatty acids) by stimulation of lipolysis
through the sympathetic nervous system [56]. Through the 90s
of the last century the interest in WAT changed from a tissue only
responsible for energy storage to a tissue that also takes part in
body metabolism. Its physiological role has changed through the
discovery of the first protein secreted from WAT: leptin [2]. More
and more proteins have been discovered that are responsible for
different functions in the body [3,57,58]. Leptin e.g. is the critical
hormone in energy balance and is produced principally by white
fat, giving the tissue an endocrine function. Other proteins are:
angiotensinogen, adipsin, acylation-stimulating protein, adiponec-
tin, retinol-binding protein, tumor necrosis factor a, interleukin 6,
plasminogen activator inhibitor-1 and tissue factor. These proteins
can work as inflammatory cytokines, some influence the lipid
metabolism and others are involved in vascular haemostasis [59].
1.4. Beige/brite adipose tissue
A special type of adipose tissue is the so called beige (or brite)
adipose tissue. Characteristics of the white adipocyte are a large
lipid droplet and a small amount of mitochondria. BAT has multi-
ple small lipid droplets, its transcriptional profile is similar to
skeletal muscle cells [60] and BAT has a large amount of mitochon-
dria which overexpress UCP1. Beige adipocytes can differentiate
in vivo from WAT or WAT precursor cells through activation pro-
cesses (e.g. b3-adrenergic receptor agonists) and then contain mul-
tiple lipid droplets and express UCP1 within their mitochondria,
which potentially makes them an important player in increasingFig. 2. Common used fatty acids for lipid metabolism imaging. a) 14(R,S)-fluoro-6-th
iodophenyl)-3-methyl-pentadecanoic acid (123I-BMIPP), d) 4,4-Difluoro-5,7-Dimethyl-4-energy expenditure and fighting against obesity [61]. This clusters
of beige cells appear e.g. through prolonged cold exposure in WAT
depots close to noradrenergic nerve fibers which trigger the beige
adipocyte recruitment [62]. Typically norepinephrine is released
from the sympathetic nerves and activates adipocyte (brown and
beige) thermogenesis. This process normally induces UCP1 expres-
sion through phosphorylation of PPARy coactivator 1alpha and
other activators [63,64]. Sidossis et al. investigated the hyperme-
tabolism in patients with burn injuries and found increased circu-
lating levels of epinephrine and norepinephrine as well as elevated
expression of UCP1 in the according WAT-areas as a result of
adrenergic stress [65]. This proves that epinephrine and nore-
pinephrine are responsible for browning of WAT which makes this
tissue able to participate in the process of non-shivering thermoge-
nesis. Alternatively, M2 macrophages are recruited to subcuta-
neous WAT during cold exposure and secret catecholamines to
activate WAT browning [66,67]. Irisin, an exercise-induced myo-
kine, can also induce browning of WAT [68,69]. This paradox find-
ing could be shown in vitro and in vivo [68] and it has been
hypothesized that this mechanism evolved from shivering muscle
contraction to support non-shivering thermogenesis by an increase
in BAT volume and has thereby a therapeutic potential to treat obe-
sity [68,69]. Another important player in WAT browning is cancer
cachexia. Through tumor-derived parathyroid hormone–related
protein (PTHrP) WAT browning is promoted and more energy is
needed in a Lewis lung cancer model [70]. Deactivation of PTHrP
inhibits WAT browning and prohibits energy wastage [70]. Besides
of the listed factors for browning there are also environmental fac-
tors, endocrine hormones and transcriptional mediators which can
cause browning of WAT [62]. Beige adipose tissue cells are only
temporarily available for thermogenesis as they develop back to
WAT-cells after activation. By other studies it could be confirmed
that beige adipocytes almost reached UCP1 levels of BAT and that
beige fat mitochondria are thermogenically active [60].1.5. Form of fatty acids (free fatty acid/triglyceride/LDL-particle)
The main suppliers of FAs taken up by BAT are TRLs (i.e. chy-
lomicrons or very-low-density-lipoprotein-particles) circulating
in the blood [71]. After incorporation into adipocytes, FAs are
stored as TGs in lipid droplets. Lately LPL-activity was found to
be important for whole body TGL clearance through BAT and
WAT [46,72]. Savonen et al. recently found a correlation between
LPL distribution and type of tissue where the FA are taken up
and identified LPL as a mandatory binding side for LDL particles
to be processed (lipolysis with exposure of FA) [73].ia-heptadecanoic acid (18F-FTHA), b) hexadecanoic acid (11C-palmitate), c) 15-(4-
Bora-3a,4a-Diaza-s-Indacene-3-Hexadecanoic Acid (BODIPY-C16).
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As already mentioned, fatty acids are the main metabolized
substance in BAT. For this reason they are used as tracers to visu-
alize adipose tissue and its metabolism.
2.1. 18F-FTHA
FTHA (Fig 2a)) was developed as a myocardial imaging agent
because a high amount of LCFA is processed in the tricarboxylic
acid cycle. It can be labelled by 18F through isotope exchange
which makes this compound an easily available PET imaging agent.
It is b-oxidized in the mitochondria and is bound irreversible to
mitochondria proteins once the sulphur group is free [74]. Maxi-
mal uptake of FTHA is similar to 11C-palmitate showing that nei-
ther the sulphur atom at the sixth position nor the introduction
of 18F has influence on the uptake kinetics [75,76]. 13F3THA analog
showed significant lower uptake and faster washout, beta-
oxidation is completely blocked by the sulphur atom at the odd
position of 13F3THA [77,78]. Radioactivity taken up by BAT was
specific to only the even-substituted thia-FTHA and transport
and metabolism steps are hindered for 13F3THA because the car-
boxyl group and the sulphur are located very close to each other.
The fatty acid is internalized through assistance of several binding
proteins in the endothelial, interstitial, and intracellular spaces
[75]. A similar mechanism for BAT as for WAT can be assumed
which makes this compound suitable for BAT imaging. In first
attempts of imaging BAT with 18F-FTHA Ouellet [79] could show
increased FA uptake in combination with an elevated 11C-acetate
uptake, as an oxidative tissue marker and therefore metabolism
indicator, in cold exposed humans. Additionally a higher 18F-FDG
uptake was reported indicating a higher energy turnover as a result
of a higher metabolic activity during cold exposure [79]. CT gave
information about the lipid density, which indicates the amount
of intracellular TGs, and a utilization of these stored TG identifies
them as the main fuel during cold exposure. These observations
are in agreement with findings in other animal models [79,80].
2.2. 11C-palmitate
Another important PET tracer is 11C-palmitate (Fig 2b)). Its short
half life of 20 min. makes an in-house cyclotron mandatory which
restricts its use significantly. Apart from that restriction palmitate
would be the optimal choice with respect to binding affinity as no
big bulky chelator molecule needs to be coupled for imaging pur-
poses. It behaves like any other natural non-synthesized fatty acid,
justifying why it is always compared to modified molecules as a
gold standard [81]. 11C-palmitate has been used as a myocardial
imaging agent in clinical examinations [82–84] but as adipose tis-
sue imaging becomes more and more important it is also used as a
fat imaging agent in clinical experiments [85]. In comparison to
BMIPP (see below) and FTHA this FA is fully metabolized and meta-
bolism products including 11CO2 are secreted by adipocytes which
is decreasing the image quality.
2.3. 123I-BMIPP
Like FTHA, BMIPP (Fig 2c)) started as a myocardial imaging
agent [86]. It is labelled with 123I through an isotopic exchange
reaction to produce a SPECT-imaging agent. Commercial availabil-
ity of BMIPP (up to 2012) and 123I as well as the easy to perform
exchange reaction [87] made this compound favourable for adi-
pose tissue imaging. A dependence on the isomeric confirmation
was shown by Lin et al. [86] and the [123I]-3(R)-BMIPP version
showed uptake suitable for clinical trials. This implies thatinternalization is not hindered by the bulky benzol ring at the
end of the FA. In comparison with palmitic acid under fasting con-
ditions, BMIPP had lower uptake into hepatocytes but similar char-
acteristic changes were observed over time [81]. So far BMIPP has
only been used by one group to image BAT and its protein contri-
bution in FA uptake [53,88].2.4. Other radiolabelled fatty acids
As already mentioned, radiolabelled fatty acids have been often
used as myocardial imaging agents in the past. The already
described fatty acids have been shown good characteristics in
terms of stability, binding affinity, pharmacokinetics etc. but there
have been others developed which will be mentioned in the fol-
lowing paragraph.
Iodine-123-hexadecanoic acid (IHXA) and iodine-123 heptade-
canoic acid (IHDA) have been developed as myocardial perfusion
agents [89,90]. Clearance kinetics for both agents were compared
with 11C-palimtate and a similar clearance was found for the fast
clearance components. The slow clearance components differed
in that way that the half time for IHXA and IHDA was only approx-
imately one fourth of that of 11C-palimtate [89,91]. These two com-
ponents represent b-oxidation and fatty acid storage in lipid pools.
This fast elimination half time makes this compound unsuitable for
SPECT as decreased image quality can be expected. In addition a
deiodination process could be observed which requires special cor-
rections to differentiate between myocardial and blood pool activ-
ity [92].
15-(p-Iodophenyl)-pentadecanoic acid (IPPA) showed a faster
myocardial clearance compared to BMIPP making it unfavorable
for SPECT as this results in image distortions and loss of quantita-
tive image accuracy [92]. This problem is caused mainly because
straight chain fatty acids are faster metabolized and cleared via
b-oxidation. The methyl-group at the b-position of BMIPP slows
down the oxidation process and improves clearance and image
accuracy in that way [93].2.5. Boron-dipyrromethene (Bodipy)
A different imaging approach is fluorescent imaging with Bod-
ipy. Because of its hydrophobic properties, Bodipy dyes can be used
for staining of lipids, membranes and other lipophilic substance
classes. High fluorescence quantum yields can be achieved due to
its wide spread p-electron system. Fluorescence of this molecule
is achieved through excitation at 503 nm and emission at
512 nm. The extension of the crude dye determines its field of
usage for imaging purposes. There are many approaches from
tumor imaging to adipose tissue detection with a fatty acid modi-
fied Bodipy. It has been proven that Bodipy C-16 (Fig. 2d)) binds
specifically to fatty acid binding proteins [94] with a similar affin-
ity as oleic acid, is incorporated into lipid droplets in hepatocytes
[95], can be quantified by fluorescent cell scanners or plate readers
[96] and can be followed downstream in metabolic processes after
uptake [97]. In a first try we were able to visualize WAT and BAT
with Bodipy-C16 specifically in vitrowith a 2 mM Bodipy C-16 solu-
tion (unpublished results), like already reported for hepatocytes
[95]. Uptake could be identified as specific uptake as the lipid dro-
plets were filled by Bodipy C-16 and no uptake in the cell nucleus
can be observed. Incorporation of the fatty acid works as already
described through protein mediation and the Bodipy dye does
not hinder the uptake qualitatively. As penetration depth of excita-
tion and emitted light cannot overcome the tissue barrier for BAT
imaging, fluorescence imaging is restricted to in vitro applications
in this approach. With its high spatial resolution it is a powerful
tool to image on a cellular level [94,96].
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By imaging adipose tissue with bioluminescence, problems of
PET and SPECT imaging, like short half life and un-physiological
uptake can be overcome [98]. To a non-esterified fatty acid probe
a luciferine derivative is coupled via a disulfide linker. This disul-
fide bridge is stable outside of the cells [99] and through reduction
by glutathione within the cell a thiol is produced which undergoes
cyclization to release free luciferine [100]. Free luciferine is than
converted to oxyluciferine and a photon of light by luciferase
[101]. Henkin et al. investigated the imaging abilities of this com-
pound and reported specific uptake as it could be blocked by oleate
in vitro. Additionally luciferine uptake frommicelles containing FA-
luciferine could be observed and BAT specific uptake in vivo could
be proven as uptake could be increased through BAT stimulation
[100].
3. Particle imaging
To image lipid metabolism there are also other pathways avail-
able apart from imaging FA. Some interesting approaches with
indirect measures for FA uptake have been reported and will be
described in this section
3.1. Fluorescence labelled nanocrystals
FA are mostly transported in TRLs through the body. At the
moment there are two assumptions about the delivery of FA
through TRLs. FA can be taken up by adipocytes after TRLs are lipo-
lyzed outside of the cell [45] or TRLs are internalized before they
are lipolyzed [46]. To investigate this process Bartelt et al. labelled
TRLs with hydrophobic fluorescent nanocrystals (QD-TRL) [46].
Quantum dots (QD) have a broad excitation and a narrow emission
range and are therefore best suited for fluorescence imaging [102].
With QD-TRLs an internalization of lipoproteins due to an increase
in permeability of the endothelial barrier function could be
observed [46]. Other applications of this imaging agent can be
thought of for quantitative and qualitative lipoprotein
incorporation.
3.2. Functional MRI
Similar to QD-TRLs, Bartelt et al. labelled lipoproteins with
hydrophobic superparamagnetic 59Fe-oxide. The intention is the
same as for QD-TGLs. The hydrophobic iron nanocrystals stay
inside of the lipoprotein and indicate if the particle is incorporated
or not. In addition the particle is filled with 3H-oleate to control
whether FA are taken up. Bartelt et al. observed a faster clearance
for the FA as well as for the nanocrystals after cold exposure indi-
cating a contribution of BAT. Total oleate and Fe-oxide concentra-
tions in cold activated mice of BAT and liver were comparable and
omitting cold exposure lead to a decrease in BAT uptake for both.
These results and the fact that 59Fe-oxide concentrations were still
increased one week after injection indicate an internalization of
the whole lipoprotein particle [46].
In contrast to these observations, the study of Khedoe et al. is
indicating an extracellular lipolysis followed by protein mediated
uptake of FA [45].
4. Other imaging techniques
4.1. MRI
With the possibility to image with a very high resolution and no
radiation dose for the patient, MRI is an important player inadipose tissue imaging. By measuring the lipid content in inter-
scapular BAT (iBAT), Grimpo et al. investigated the response to cold
exposure and noradrenaline stimulation for wild type and UCP1
knock-out mice. Lipid content was the same for both groups under
all temperature conditions with less FA stored in lipid droplets
after cold exposure. A faster noradrenaline response could be
observed in wild type mice [103]. Additionally in the study of Hol-
stila et al. MRI was identified as a more adequate method to iden-
tify and quantify BAT, independently of its activation state,
compared to PET/CT with 18F-FDG. BAT masses calculated with
PET/CT were significant smaller than the masses obtained through
dissection. MRI provided more accurate information even if a small
overestimation has been observed. Advantageous is the indepen-
dence of the activation state as this method is measuring the
water/lipid content and compares it with previous records. For
the same reason no cold exposure is necessary to activate BAT. A
successful human pilot study was performed too by this group
[104]. Additionally first studies have been done in adult humans
with FDG-PET/CT as a reference standard by van Rooijen et al.
[105]. In comparison to the mentioned studies in animal models
[106–109], they could not discern active BAT on the basis of tissue
fat content. Dynamic BAT activation could be identified by
T2⁄-weighted MRI during cold stimulation. Even though PET pro-
vides images of active BAT with a higher contrast, MRI is capable
in gaining additional information such as: temporal and quantita-
tive measurements of tissue fat content, changes in blood flow, vol-
ume, and oxygenation of active BAT [105].4.2. CT
A standalone computed tomography to identify BAT seems in
terms of a lower radiation dose compared to PET/CT a good choice
but without PET it is almost impossible to identify BAT by the dif-
ference in Hounsfield units and gets even more complicated when
WAT is located next to it. So most of the recent studies are PET/CT
related and some indicate PET/CT with 18F-FDG not as the optimal
choice [110]. Another problem is the difference in interpreting the
Hounsfield units as adipocytes. Gortel et al. used a threshold
of 200 to 30, Maurovic- Horvat et al. used a threshold
from 149 to 30 and Mahabadi et al. a threshold of 195
to 45 [111–114]. By having this differences an under or overesti-
mation is easily possible and does not really describe the amount
of BAT. Because of the listed reasons a CT on its own is not capable
in identifying BAT and also a PET/CT with 18F-FDG is not the best
choice anymore. There are several better compounds which target
BAT without activation and also MRI seems to have more advan-
tages and a more accurate way to identify adipocytes.5. Ex vivo methods
5.1. 3H-Triolein
Tritium does not have the optimal properties for non-invasive
imaging. Its really soft radiation makes it impossible to detect it
from outside of the body because the emitted electrons are
stopped after a few micrometers in tissue. Its field of application
is supported by its favourable biodistribution and plasma extrac-
tion. By that method the uptake at certain time points can be
tested by the fraction of Triolein still present in the blood
[46,76]. An impact of cold exposure or BAT activation through
noradrenaline can be observed but not a clear quantification of adi-
pocyte uptake can be achieved as lipids can be taken up by other
tissues or cleared from the blood.
3H-triolein is also used in autoradiography studies. Stein et al.
investigated metabolism steps of starved rat fat cells and found
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esterified fatty acids were in the form of diglycerides, less than 1%
were monoglycerides and the rest were TG. They assumed there-
fore the esterification of diglycerides to TG as the rate limiting step
in the TG synthesis in adipose tissue. Four fifth of the signals
observed were found within the lipid droplets of the cell identify-
ing them as the primary destination for newly taken up FA [115].
5.2. ADIFAB staining
ADIFAB is a stain for unbound fatty acids and is only applicable
in in vitro work. Acrylodan labelled rat intestinal fatty acid binding
protein (ADIFAB) is fluorescent if it is bound to a fatty acid. Kampf
et al. [116] investigated the change in cytosolic unbound FA in
response to a change in extracellular unbound FA. They discovered
an influx concentration dependence of membrane carrier proteins
which could be saturated and a strong influence of translocation
for the fatty acid uptake ratio [116]. Other experiments have been
done to examine the fatty acid uptake mechanism in vitro with
ADIFAB and identified flip-flop as the rate limiting step for oleate
transport through the lipid bilayer membrane [117].
6. Conclusion
Lipid metabolism imaging has a broad field of application. It is
generally accepted in terms of myocardial imaging, hepatic imag-
ing etc. Our focus was to outline its broad function in fields within
the whole body and specifically for the use to visualize adipose tis-
sue and its metabolism. Its fast developing field within the niche of
adipose tissue imaging draws attention to new imaging
approaches and agents and helps to understand more and more
this, for a long term, underestimated tissue. We expect radiola-
belled fatty acids to be the most promising agents in clinical
research to unravel adipose tissue processes in BAT for the next
years but also fluorescent imaging, with its ability to image on sub-
cellular level, and MRI should not be underestimated and will con-
tribute to the exploration of adipose tissue and lipid metabolism.
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